Audit: QRS - Bromelain for Health & Longevity

Audit conducted on 07/09/2026 06:00 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢
1.6	The QRS does not introduce new attributions.	🟢

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No section of the source ER is empty; every source section carries content, so no empty-state phrasing is required.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.2	[at_a_glance] is no longer than 60 words	🟢
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The [stop_items] span is not empty (5 contraindications carried over from the ER).

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The [caution_items] span is not empty (8 interactions carried over from the ER).

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section provides more than three distinct actionable implementation aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (Practical Considerations, “Time to effect”), so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers (high, medium, low, speculative) carry items in the ER; no sub-section is empty.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers (high, medium, low, speculative) carry items in the ER; no sub-section is empty.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢

Issues 07/09/2026 06:00

Pass rate 100.00%. No issues found.

Issues 07/09/2026 05:53

1. 4.2 — NSAID label not verbatim: The third Key Interactions item (QRS lines 602-603) reads “Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen):” while the ER bold label (ER line 326) includes a third example, “low-dose aspirin”.
2. **4.3 — marker_7why paraphrased:** QRS line 755 reads “Flags the one potentially serious risk”; the ER’s “Why Measure It?” cell (ER line 466) reads “Identifies the one potentially serious risk before exposure”, and every other marker#_why is carried verbatim.

Fixes 07/09/2026 05:53

1. 4.2 — NSAID label made verbatim: Restored the ER’s third example drug in the Key Interactions bold label, from “(ibuprofen, naproxen)” to “(ibuprofen, naproxen, low-dose aspirin)”.
2. 4.3 — marker_7_why restored to ER wording: Replaced the paraphrase “Flags the one potentially serious risk” with the ER’s “Identifies the one potentially serious risk before exposure”.

Issues 07/09/2026 05:47

1. 1.3 — Potency equivalence stated unconditionally: [action_3_value] (QRS line 480) gives “1,200 gelatin digesting units per 500 mg” as a fixed equivalence, while the ER Therapeutic Protocol conditions it on potency: “A 2,400-unit-per-gram powder at 500 mg supplies about 1,200 gelatin digesting units.”
2. 1.3 — “high-dose” dropped from vitamin E: [caution_items] (QRS line 616) lists “vitamin E” among the additive-antiplatelet supplements, whereas the ER Key Interactions & Contraindications bullet specifies “high-dose vitamin E”, broadening the caution beyond what the ER supports.
3. 2.6 / 2.9 — Imperative addresses the reader: [marker_8_target] (QRS line 764) reads “No fixed target; track change from own baseline” — an imperative with a dangling possessive; the ER wording is “track change from the individual’s own baseline”.

Fixes 07/09/2026 05:47

1. 1.3 — Potency equivalence hedged: [action_3_value] changed from “1,200 gelatin digesting units per 500 mg” to “About 1,200 gelatin digesting units per 500 mg”, and [action_3_sub] now carries the ER’s premise, “From a 2,400-unit-per-gram powder; milligrams alone say nothing about actual protease activity.”
2. 1.3 — “high-dose” restored for vitamin E: The antiplatelet-stacking parenthetical in [caution_items] changed from “vitamin E” to “high-dose vitamin E”, matching the ER bullet.
3. 2.6 / 2.9 — Reader-directed imperative removed: [marker_8_target] changed from “No fixed target; track change from own baseline” to “No fixed target; change from the individual’s own baseline”.

Issues 07/09/2026 05:39

1. 10.2 — Potency bullet omitted from Protocol: action_3 uses “Best time of day” (line 476) while the ER’s “Potency, not weight, is the real dose” bullet — the ER’s own headline dosing caveat, echoed in the At-A-Glance — has no protocol cell.
2. 4.5 — Content exceeds one A4 page: The combined 8-row Monitoring table, 8 Key Interactions (lines 590-625) and 6 Qualitative items (lines 785-817) push the sheet past a single A4 page at the template’s type sizes.

Fixes 07/09/2026 05:39

1. 10.2 — Potency replaces timing in Protocol slot 3: action_3 was changed from “Best time of day / At least 45 min before or 2 h after food” to the ER’s “Potency, not weight, is the real dose / 1,200 gelatin digesting units per 500 mg”, with the sub reading “Milligrams alone say nothing about actual protease activity.”
2. 10.2 — Fasted-window timing folded into systemic dose: action_1_sub now reads “Stem bromelain in two or three divided doses, at least 45 min before or 2 h after food. Colitis benefit at 400 mg daily.”, preserving the timing detail freed from slot 3.
3. 4.5 — Key Interactions condensed: Trimmed the parenthetical drug lists on three items — dropped “low-dose aspirin” from the NSAID item, “serrapeptase” and “high-dose” from the antiplatelet-supplement item, and “trypsin-rutoside blends” from the anti-inflammatory-supplement item.
4. 4.5 — Contraindication shortened: “Active peptic ulcer or active gastrointestinal bleeding” reduced to “Active peptic ulcer or gastrointestinal bleeding”.
5. 4.5 — Monitoring cells shortened: marker_7_why changed from “Identifies the one potentially serious risk before exposure” to “Flags the one potentially serious risk”, and marker_8_target from “track change from the individual’s own baseline” to “track change from own baseline”.
6. 4.5 — Cadence and qualitative items tightened: monitoring_cadence shortened to “clotting studies at 1-2 weeks on anticoagulants”; qualitative item 1 dropped “and lighting” and item 6 was condensed to “New bruising, gum bleeding or nosebleeds: earliest anticoagulant signal”.

Issues 07/09/2026 05:33

1. 1.1 — Dropped “at least” from dosing window: [action_3_value] (line 479) states “45 min before or 2 h after food”, but the ER Therapeutic Protocol says “at least 45 minutes before or 2 hours after food”; removing the minimum qualifier turns a floor into a point value that the ER does not state.

Fixes 07/09/2026 05:33

1. 1.1 — Restored “at least” in dosing window: [action_3_value] changed from “45 min before or 2 h after food” to “At least 45 min before or 2 h after food”, restoring the ER’s minimum-interval qualifier.

Issues 07/09/2026 05:25

1. 4.5 — Sheet overflows one A4 page: Measured against the print stylesheet (A4 minus 12 mm padding = 774 pt usable), the populated sheet totals roughly 1468 pt, about 1.9 pages; the decision-gates block (~335 pt, Key Interactions runs 21 wrapped lines at lines 592-628), Monitoring (~317 pt) and Qualitative Assessment (~144 pt) are the largest over-budget blocks.
2. 2.8 — Time-to-effect sub-lines restate label and value: Lines 505, 517 and 530 add no information beyond the label and value already shown in the same cell (e.g. “Colitis activity” / “8 weeks” / “Colitis activity scores shifted over eight weeks.”), and several qualitative items and action sub-lines are longer than the compact format requires.

Fixes 07/09/2026 05:25

1. 2.8 — Time-to-effect sub-lines rewritten: All three sub-lines were replaced with non-redundant ER facts instead of restatements of their own label and value: course lengths (“Perioperative courses run 3-14 days; sinus courses 5-10 days.”), the single-trial caveat for colitis, and the combination-product caveat for joint outcomes.
2. 2.8 / 4.5 — Protocol sub-lines condensed: The three action sub-lines were tightened without losing ER content, e.g. “Taken with each protein-containing meal; targets food protein in the stomach and does not depend on absorption.” became “With each protein-containing meal; acts on food protein, not via absorption.”
3. 4.5 — Qualitative Assessment items shortened: All six items were compressed to a single rendered line each (e.g. “Any new bruising, gum bleeding or nosebleeds, the earliest practical signal of an anticoagulant interaction” → “New bruising, gum bleeding or nosebleeds, the earliest anticoagulant-interaction signal”).
4. 4.5 — Antiplatelet supplement list trimmed: The supplement names in the additive-antiplatelet interaction were shortened from “garlic extract, Ginkgo biloba” to “garlic, ginkgo”, keeping “high-dose vitamin E” and every listed agent, which removes one wrapped line from the Key Interactions column.
5. 4.5 — Residual overflow noted: The measured sheet fell from ≈1468 pt to ≈1430 pt; the remaining excess sits in the Monitoring table (8 rows), Key Interactions (8 items) and Contraindications (5 items), which items 14.2, 9.2 and 8.2 require to be listed in full, so no further content could be removed without breaking those items.